Pharmacotherapy for overactive bladder: An evidence-based approach to selecting an antimuscarinic agent

Drugs

Volumn 66, Issue 10, 2006, Pages 1361-1370

  Appell, Rodney A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARIFENACIN; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M3 RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE; TRIACETIN; TROSPIUM CHLORIDE;

ANTICHOLINERGIC EFFECT; APPLICATION SITE REACTION; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; COUGHING; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY THROAT; ERYTHEMA; EVIDENCE BASED PRACTICE; FIRST PASS EFFECT; HEADACHE; HEART DISEASE; HUMAN; HYDROPHILICITY; INSOMNIA; MICTURITION DISORDER; NEUROMUSCULAR SYNAPSE; OVERACTIVE BLADDER; PRURITUS; REVIEW; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; UNITED STATES; URINE INCONTINENCE; XEROSTOMIA;

EVIDENCE-BASED MEDICINE; HUMANS; MUSCARINIC ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, MUSCARINIC M3; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC;

EID: 33747351573     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666100-00005     Document Type: Review

References (33)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 2002; 21 (2): 167-78
2. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20 (6): 327-36
3. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6 (11 Suppl.): S574-9
4. Jeong GL, Jae YH, Myung-Soo C, et al. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol 2002; 9 (5): 247-52
5. Leung HY, Yip SK, Cheon C, et al. Tolterodine and oxybutynin had similar tolerability and efficacy for the treatment of overactive bladder. EROG 2003; 5 (2): 88-9
6. Malone-Lee J, Whately-Smith C. A study of the significance of identifying detrusor instability in the treatment of overactive bladder symptoms [presentation]. 34th meeting of the International Continence Society; 2004 Aug 23-27; Paris
7. Anderson RU, Brown JS, Mobley D, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999; 161 (6): 1809-12
8. Barkin J, Corcos J, Radomski S, et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther 2004; 26 (7): 1026-36
9. Birns J, Malone-Lee JG, Lukkari E. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10mg once daily) with conventional oxybutynin tablets (5mg twice daily) in patients whose symptoms were stabilized on 5mg twice daily of oxybutynin. BJU Int 2000; 85 (7): 793-8
10. Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000; 95 (5): 718-21
11. van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57 (3): 414-21
12. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62 (2): 237-42
13. Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 2005; 27 (1): 127-38
14. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001; 41 (6): 636-44
15. GlaxoSmithKline. VESIcare (solifenacin succinate) prescribing information. GlaxoSmithKline, 2004 Nov
16. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 2001; 76 (4): 358-63
17. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78 (6): 687-95
18. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45 (4): 420-9
19. Steers W, Corcos J, Foote J, et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU International 2005; 95 (4): 580-6
20. Hill S, Khullar V. Darifenacin, a muscarinic receptor antagonist with selectivity for m3 receptors, reduces incontinence and nocturia in patients with overactive bladder [abstract]. 34th meeting of the International Continence Society; 2004 Aug 23-27; Paris
21. Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005; 95 (7): 993-1001
22. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172 (5 I): 1919-24
23. Chapple CR, Rechberger T, Al Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93 (3): 303-10
24. Chapple C, Jonas U, Chancellor M, et al. New antimuscarinic agent, solifenacin succinate, reduces urgency episodes in overactive bladder: an analysis of over 3000 patients [poster]. EAU Annual Meeting; 2004 Mar 24-27; Vienna
25. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended-release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464-70
26. MacDiarmid SA. Overactive bladder: improving the efficacy of anticholinergics by dose escalation. Curr Urol Rep 2003; 4: 446-51
27. Frohlich G, Bulitta M, Strosser W. Trospium chloride in patients with detrusor overactivity: meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20mg trospium chloride twice daily. Int J Clin Pharmacol Ther 2002; 40 (7): 295-303
28. Zinner N, Auerbach S, Gittelman M, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171 (6 I): 2311-5
29. Rudy D, Cline K, Goldberg K, et al. A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients. 34th meeting of the International Continence Society; 2004 Aug 23-27; Paris
30. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003; 20 (6): 392-9
31. Pietzko A, Dimpfel W, Schwantes U, et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994; 47 (4): 337-43
32. Katz IR, DiFilippo S, Boyce A, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46 (1): 8-13
33. Chapple C, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005; 48 (1): 5-26